Grand Pharma (China) Co., Ltd.

Grand Pharmaceutical Group Limited (Hong Kong stock code 00512.HK), with a history dating back to 1939, is a technologically innovative international pharmaceutical company headquartered in Wuhan. Its business covers nuclear drug anti-tumor diagnosis and treatment, cardiovascular and cerebrovascular precision interventional diagnosis and treatment, respiratory and critical care, five senses, cardiovascular and cerebrovascular first aid, API plates and high-quality amino acids. The Group has 8 R&D centers around the world, more than 770 R&D personnel, and more than 133 research projects. It continues to promote the "Go Global" global innovation strategy and in-depth cooperation with innovative pharmaceutical products and scientific research institutions in the United States, Australia, Germany, Belgium and other countries. Its business segment includes the "API segment" and "high-quality amino acids". However, the official website mainly focuses on the fields of nuclear drugs, cardiovascular and cerebrovascular interventions, mRNA and other innovative pharmaceutical devices, and does not specifically introduce polypeptide APIs.

Grand Pharma (China) Co., Ltd. is located at No. 11, Jinyinhuhuanhuzhong Road, Dongxihu District, Wuhan, China.

Finished peptide dosage forms available.